Table 1.
Patient Clinical and Demographic Characteristics at Baseline
| Patients (N = 306) | n (%) |
|---|---|
| Age (y) | |
| Median (range, y) | 67 (27–92) |
| <70 | 180 (58.9) |
| 70–79 | 95 (31) |
| ≥80 | 31 (10.1) |
| Sex | |
| Male | 181 (59.2) |
| Female | 125 (40.8) |
| Body mass index | |
| Median, kg/m2 (Q1–Q3) | 24.9 (21.8–27.9) |
| Histologic diagnosis | |
| Lung Non-SCC | 211 (68.9) |
| Lung SCC | 49 (16) |
| Lung NSCLC | 260 (84.9) |
| Lung SCLC | 22 (7.2) |
| Pleural mesothelioma | 13 (4.2) |
| Othersa | 11 (3.5) |
| Last treatment received <3 mo | |
| Chemo-based regimen | 74 (24.2) |
| Immunotherapy alone | 48 (15.7) |
| Oral TKI or bevacizumab alone | 43 (14) |
| No systemic treatment (radiotherapy, surgery, and complete response) | 141 (46.1) |
| Chronic radiation pneumonitis | |
| Yes | 37 (12.1) |
| No | 269 (87.9) |
| Previous thoracic surgery | 89 (29) |
| Pneumonectomy | 6 (1.95) |
| Lobectomy or sublobar resection | 79 (25.8) |
| Thymectomy or mediastinal tumor resection | 4 (1.3) |
| Duration of disease | |
| Median, mo (Q1–Q3) | 17.3 (6.4–35.3) |
| ≥12 mo | 189 |
| <12 mo | 117 |
| Long-term corticosteroid treatment | |
| Yes | 20 (6.5) |
| No | 286 (93.5) |
| Disease extent | |
| Metastatic | 175 (57.2) |
| Local or locoregional | 131 (42.8) |
| Disease status | |
| Response or stable | 211 (69.0) |
| Progressive | 95 (31.0) |
| T-lymphocyte count available at d 28 | 122 (39.9) |
| Median/mm3 (Q1–Q3) | 1129 (742–1434) |
| CD4+ count available at day 28 | 122 (39.9) |
| Median/mm3 (Q1–Q3) | 596 (345–853) |
| COVID–19 history before first vaccination | |
| Yes | 19 (6.2) |
| No | 287 (93.8) |
| Type of vaccine | |
| Pfizer BNT 162b2 | 302 |
| Moderna 1273 | 1 |
| AstraZeneca ChAdOx1 nCOVID–19 | 3 |
Chemo, chemotherapy; COVID-19, coronavirus disease 2019; Q, quartile; SCC, squamous cell cancer; TKI, tyrosine kinase inhibitor.
a
Five thymic carcinomas, four carcinoid tumors, one hemangioendothelioma, and one hamartochondroma.